|Bid||61.49 x 100|
|Ask||61.51 x 200|
|Day's Range||60.61 - 62.09|
|52 Week Range||54.66 - 84.88|
|PE Ratio (TTM)||17.91|
|Earnings Date||Feb 5, 2018 - Feb 9, 2018|
|Forward Dividend & Yield||1.85 (3.07%)|
|1y Target Est||68.00|
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Cardinal Health, Inc. Here are 5 ETFs with the largest exposure to CAH-US. Comparing the performance and risk of Cardinal Health, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Medtronic's CVG (Cardiac and Vascular Group) business reported growth of ~7.0% on a YoY (year-over-year) basis.
Announcement: Moody's: Pharma manufacturers and distributors face rising risks related to US opioid crisis. Global Credit Research- 30 Nov 2017. New York, November 30, 2017-- A number of pharmaceutical ...
DUBLIN, Ohio, Nov. 30, 2017 /PRNewswire/ -- Cordis, a Cardinal Health company, and Medinol today announced United States Food and Drug Administration (FDA) approval of the EluNIR™ drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR™ stent system is designed with a novel metallic spring tip and the narrowest strut width of any stent on the U.S. market to help clinicians easily deliver this new DES in highly complex anatomy and disease. The EluNIR™ DES demonstrated outstanding efficacy and safety results in two randomized clinical trials, including BIONICS, a global pivotal study of 1,919 patients from 76 sites in eight countries.
A scarcity of lethal injection drugs nationwide drove plans to use a never-before-tried three-drug combination for Nevada's first execution in more than 11 years, the state's former top doctor told The ...
Stock Monitor: Cardinal Health Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors' free earnings report on McKesson Corp. (NYSE: MCK ) has freshly been issued to its ...
NEW YORK, Nov. 28, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Garmin ...
Amazon.com, Inc. (NASDAQ: AMZN ) poses an existential threat to a host of retailers, and even to companies outside the retail arena. Drug distributor Cardinal Health Inc (NYSE: CAH ) could be one among ...
Cardinal Health Inc. shares declined 3.4% in premarket trade Monday and McKesson Corporation shares declined 2.4% after Morgan Stanley said they were two of the companies most at risk if Amazon expands ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Consumer Services sector is rising.
DUBLIN, Ohio, Nov. 16, 2017 /PRNewswire/ -- Cardinal Health (CAH) today launched its new Opioid Action Program, aimed at helping communities in four of the nation's hardest-hit states across Appalachia combat the opioid epidemic. The pilot program will deliver much needed front-line tools to help prevent opioid abuse and support first responders in Ohio, Kentucky, Tennessee and West Virginia. The Opioid Action Program has four elements, each cited by leading experts as critical to the fight to reduce opioid abuse and casualties.
Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc's China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide. The deal will also help Shanghai Pharma, China's third largest drug distributor, become a leading importer of foreign medicine into the world's second-largest drug market.
Shanghai Pharmaceuticals Holding Co has agreed to buy Cardinal Health Inc's China drug distribution business for $557 million, winning a highly competitive auction in a move that will greatly expand its presence nationwide. The deal will also help Shanghai Pharma, China's third largest drug distributor, become a leading importer of foreign medicine into the world's second-largest drug market. Including shareholder loans, the deal gives Cardinal's business in mainland China and Hong Kong an enterprise value of $1.2 billion, equivalent to about 15 times its earnings before interest, taxes, depreciation and amortisation (EBITDA) for the year ended June.
Cardinal Health Inc. has sold its distribution business in China to one of the country's largest publicly traded pharmaceutical groups for $1.2 billion, but is keeping a foothold in the country with its higher-margin services. Dublin-based Cardinal was the first of the big three U.S. health care distributors to enter the world's second-largest economy six years ago. It acquired the former Yong Yu and over two years, added smaller companies for a combined $578 million .
Cardinal Health Inc (NYSE: CAH ) is seeing continued margin contraction at its Pharma Distribution segment. An analyst at Argus thinks this trend would continue, pressuring the stock. The Analyst & The ...
Cardinal Health (CAH) will streamline its Chinese operations by disposing pharmaceutical and medical products distribution business in China.
Shanghai Pharmaceuticals Holding Co. is exploring further acquisitions after it beat out global buyout firms to buy Cardinal Health Inc.’s Chinese distribution business in a $1.2 billion deal.
The U.S. pharmaceutical company, which has taken a hit from falling generic-drug prices, is unloading its distribution operations as Beijing tightens oversight of the industry.
The CNBC IQ100 index beating the broader market over one year up over 19%. Today's leaders include Teva Pharma, Cardinal Health and Mattel. The laggards Sony, Kimberly-Clark and Clorox.